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Abstract 
Lung adenocarcinoma is the most common type of non-small cell lung cancer, causing more 
than 500,000 deaths per year worldwide [5].  This research aims to investigate the role of Fas-
associated protein with death domain (FADD) in lung adenocarcinomas in hopes of identifying a 
clinical biomarker and/or therapeutic target for the disease.  Recent studies in lung cancer have 
indicated a correlation between phosphorylated FADD (p-FADD), induction of Nuclear Factor- 
KappaB (NF-κB) and poor clinical outcome [6].  The precise role of FADD in these cancers is not 
well understood.  Here we aimed to elucidate its role in cancer by using a genetically 
engineered mouse model, which allowed for tissue specific FADD deletion simultaneous to 
activation of oncogenic KrasG12D.  This model enabled evaluation of differential lung cancer 
development in the presence or absence of FADD expression.  Infecting the lungs with 
adenovirus expressing Cre recombinase allowed for inducible excision of FADD simultaneous to 
KrasG12D activation.  After treatment with Cre recombinase, mice consistently developed lung 
tumors in the presence of FADD expression, while in mice wherein FADD was simultaneously 
deleted, tumor progression was inhibited.  In addition, fibroblasts isolated from FADD deficient 
lungs grew more slowly in culture than fibroblasts from lung tissue expressing FADD.  These 
findings support our hypothesis that FADD is required for lung tumor cell growth and provide 
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Background 
 Lung cancer causes more deaths of both men and women worldwide than any other type of 
cancer [13, 14].  The American Cancer Society has predicted that over 220,000 new patients will be 
diagnosed with lung cancer in 2013, and 165,000 Americans will die from it this year [14].  
Adenocarcinoma is the most common type of non-small cell tumor, accounting for over 40% of all lung 
malignancies [13].  Their metastatic tendencies, slow growth and asymptomatic presentation in 
peripheral lung tissues make adenocarcinomas especially deadly [5].    
 Recent explorations into the cellular basis for lung cancer have focused on the activation of 
oncogenes and the loss of tumor suppressors [9].  These opposing gene types comprise a tightly 
regulated system of checks and balances.  When mutations are introduced, these genes may become 
weaker or stronger, disturbing this delicate balance.  When Kras becomes mutated, it acts through the 
cell proliferation pathway and actuates unwarranted proliferation [15].  In many cancers, these effects 
are exacerbated by loss of essential tumor suppressor genes.  For example, protein kinase C (PKC) is a 
tumor suppressor that normally acts to restrict signaling from mutant Kras.  When PKC undergoes a loss 
of function mutation, Kras is further enabled and homeostasis is further disturbed [10].   
Apoptosis is an indispensible homeostatic mechanism that allows for the proper growth of 
eukaryotic organisms.   In C. elegans, apoptosis plays a crucial role during an invariable developmental 
process in which 131 of the total 1090 healthy cells undergo a highly regimented pattern of 
programmed cell death [2].  Apoptosis plays a crucial role by eliminating self-reactive immune cells, by 
sculpting organs during embryogenesis, and by destroying damaged and cancerous cells.  In the extrinsic 
apoptosis pathway, ligands such as APO-3, TRAIL, TNF-α/β, and Fas bind to corresponding membrane 
bound death receptors which transmit their signals through an intracellular death domain that binds to 
a diverse array of proteins [2].  Fas-associated protein with death domain (FADD) is a cytosolic adapter 
protein that utilizes its C-terminal death domain to bind the cytosolic death domain of trimerized Fas, 
TRAIL and other receptors [11].  Binding to the death domain unmasks the N-terminal effector domain 
of FADD allowing it to cleave procaspase-8, initiating the serine protease cascade leading to apoptosis 
[11]. 
Counteracting the cell’s apoptotic pathways are proliferation pathways initiating cell growth and 
division.  When one of the proteins in this pathway is mutated, it can lead to loss of cell cycle control, 
which is a hallmark of cancer [9].  For this reason, the genes and mutations involved in cell growth are of 
great interest to those studying cancer.  While FADD is primarily known as part of the apoptotic 
pathway, its role in promoting cell division has recently been characterized [4, 11].   Phosphorylated 
FADD (p-FADD) is necessary for progression through metaphase of mitosis [4].  FADD’s role in both 
apoptosis and cell proliferation makes it a complex yet promising target for cancer researchers.   
Recent research has correlated increased FADD concentrations with lung cancer and poor 
clinical prognosis [4].  However, it is unknown if this change in FADD levels is a cause of, or a response to 
the cancer.   Also, there is disagreement on whether FADD is acting as a tumor suppressor or an 
oncogene [1, 4].  We hypothesized that FADD’s oncogenic potential in lung cancer stems from its role in 
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regulating cell cycle.   FADD acts in an oncogenic capacity by allowing lung cells to progress unchecked 
through the cell cycle, which is a highly common oncogenic mechanism. 
In order to create a model system that is faithful to human adenocarcinomas, we used a mouse 
model in which tumor development and FADD expression were under our control. These criteria were 
met by combining two previously described mouse models.  To create a tumor inducible system, a 
mutation in the Kras cell proliferation pathway was employed.  Kras is an intracellular signal transducer 
responsible for transmitting growth and proliferation signals [12, 15].  Activating mutations in Kras have 
been implicated in nearly 25% of lung tumors [15].  Characterization of these mutations indicates that a 
missense mutation at the 12th codon causes constitutive activation of downstream cell proliferation 
pathways, eventually leading to cancer [12]. To achieve tissue specific and inducible oncogenic KrasG12D 
expression a mouse model carrying a knock-in allele with a stop codon preceding the mutant Kras 
(KrasG12D) was employed [8].  Treatment with Cre recombinase recombined the DNA at the loxP sites 
flanking the stop codon, thereby removing the stop and enabling transcription of oncogenic KrasG12D.    
Mice without FADD die in utero, thus requiring an alternative strategy to study FADD’s 
requirement for tumor formation [19].  Exogenous expression of a conditional FADD transgene 
overcomes this hurdle and has been developed by Zhang et al [19]. These mice were further crossed 
with the inducible mutant Kras model described by above, thereby achieving a mouse model wherein 
FADD deletion and KrasG12D activation represent simultaneous events in lung pathogenesis [18].  Using 
this mouse model allowed us to create mice with lung tumors and variable FADD genotypes.  Comparing 
these experimental cohorts allowed us to isolate the variable of FADD expression in lung cancers.   
Lung cancer causes more deaths than any other form of cancer [5, 14].  Efforts to diagnose and 
treat this devastating disease have been largely unsuccessful.  In search of a new biomarker and/or 
therapeutic target for lung cancer, this research aimed to investigate the role of FADD in cancer 
progression.  To accomplish this, a mutant Kras driven mouse model with conditional FADD expression 
was employed.  We were able to experimentally demonstrate the success of KrasG12D mediated lung 
cancer induction and FADD suppression upon infection with Cre recombinase using histology and 
Western blot analysis.  FADD transgene excision led to decreased growth potential of murine lung 
fibroblasts in tissue culture.  These results confirm our initial hypothesis that FADD promotes cancer and 
may serve as a therapeutic target in the treatment of lung cancer.  The proposed mechanism for FADD’s 
role in tumorigenesis involves deregulation of cell cycle leading to self-stimulated growth, a hallmark of 
cancer [9].   Future goals of this research involve mechanistically investigating FADD’s oncogenic role in 
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Results 
Characterization of novel KrasG12D driven mouse model with conditional FADD expression 
Having a mouse model in which lung cancer is readily and consistently inducible is crucial to 
designing experimental directives.  To do this, we used a well-characterized mutation in the Kras cell 
signaling protein [12].  This conditionally activatable allele of oncogenic Kras harbors a missense 
mutation at codon 12, thus interfering with GTPase activity and leading to constitutive signaling down 
the proliferative MAP-Kinase pathway leading to cancer [8, 18]. To attain tissue specific KrasG12D 
expression a mouse model was used, where KrasG12D was knocked in along with a loxP mediated 
excisable stop codon (Figure 1 A).  Once mice reached adulthood, treatment with adenovirus Cre lead to 
successful removal of the preceding stop codon, and enabled transcription of the mutant Kras (Figure 1 
A).  Due to the difficulty of specifically identifying mutant Kras in a Western Blot, we probed for p-ERK as 
a surrogate protein target.  p-ERK actuates downstream cell proliferation mechanisms initiated by Kras, 
and is found to be in higher concentration when KrasG12D is activated.  
 In order to study the impact of FADD in developing lung cancers, it was necessary to regulate 
FADD protein levels in the cell.  To do this, a mouse model was attained from the Zhang lab that had 
FADD knocked out of one or both alleles [19].  Since FADD is essential for normal development, a 
conditional transgene was inserted containing a FADD:GFP fusion gene.  Previous research 
demonstrated FADD’s ability to functionally tolerate this insertion [19, 21].  In order to combine the two 
models discussed above, mice from each strain were crossed (Figure 1 B).  Four experimental cohorts 
were successfully established, as confirmed by genotyping PCRs (data not shown). As depicted in Figure 
1C, western blot analysis using a GFP antibody confirmed successful transgene depletion in lung tissue.  
Endogenous FADD protein expression status was confirmed in tissue acquired from FADD ko/ko and 
FADD ko/+ mice by using anti-FADD antibody.   
 By cross breeding previously distinct murine lines, we were able to successfully establish a Kras 
driven lung cancer model with conditional FADD expression.  Using Western blots to analyze gene 
expression allowed us to confirm the success of this breeding and to separate the resultant mice into 
four distinct experimental cohorts (Figure 1 B).    
Induction of lung cancer following KrasG12D activation 
 To demonstrate that the effects of mutant Kras are observed in the mouse and not only in tissue 
culture, KrasG12D was activated in the lungs of mice whose lungs were then evaluated by histology.  The 
experimental cohort was selected to have wild type and mutant Kras expressing mice, as well as having 
normal FADD expression levels in all mice.  This allowed us to isolate the variable of KrasG12D activation.  
Analysis of lung histology after KrasG12D activation illustrates the tumorigenicity of mutant Kras.  KrasG12D 
mice developed severe tumors and hyperplasias, while wild type Kras mice appeared healthy (Figure 2 
A).  
 Next, it was necessary to confirm the expression profiles of the mice used in these experiments.  
In order to confirm activation of oncogenic KrasG12D in mouse lung tissue by Western blot and 






























Figure 1: Developing the mouse model.  A. Gene schematic for the FADD:GFP transgenic construct and KrasG21D 
knock in construct.  loxP mediated excision of transgene by Cre recombinase is indicated.  KrasG21D knock in construct 
containing an excisable STOP codon with flanking loxP sites.  Transcription is enabled by Cre recombinase as 
indicated.  B. Establishment of experimental cohort.  KrasG12D lsl/+ denotes knock in of mutant Kras with loxP flanked 
STOP codon.  C. Western Blot of liver and lung tissues demonstrating endogenous and transgenic FADD expression 
after intranasal instillation with Ad-Cre.  D. Western Blot of lung tissue demonstrating p-ERK activity as a surrogate 
for KrasG12D expression. 





















Figure 2: Oncogenic Kras activation. A. Microscope scans of haematoxylin and Eosin Y stained murine lung cross-
sections after treatment with Ad-Cre.  Arrows indicate lesions in the KrasG12D lungs.  B. Western blot 
demonstrating lower p-ERK concentration in murine lung tissues lacking FADD. Two distinct bands represent the 
two subunits of p-ERK. C.  p-ERK staining of murine lung cross-sections taken at 40X magnification.  Brown 






















         7 
 
immunohistochemistry, it was necessary that we had an antibody specific to mutant Kras specifically, 
and not total Kras.  The difference between these proteins is only a single amino acid.  Since this 
antibody has not been commercially produced yet, we selected a surrogate protein downstream of Kras 
that increases in concentration upon Kras activation: p-ERK (Figure 2 G).  Since mutant Kras is 
constitutively signaling for proliferation, p-ERK should be in higher concentration in tissues where 
KrasG12D is being expressed.   
In order to further demonstrate that Kras activation leads to p-ERK up-regulation, 
immunohistochemistry was carried out on cross-sections of lung tissue acquired from the mice of our 
experimental cohort.  This approach allowed for spatial determination of p-ERK expression, and 
demonstrated a strong association between Kras induced lesions and p-ERK expression in tissues from 
both genotypes (Figure 2 C).  
Precise quantification of p-ERK was not possible by the immunohistochemistry technique, so we 
turned to the Western blot as a more quantifiable approach.  Through these studies of p-ERK in our 
FADD knockout model, we serendipitously discovered a connection between FADD expression and p-
ERK expression (Figure 1 D).  In lung tissues where FADD had been knocked out, we noticed that p-ERK 
concentrations were significantly lower (Figure 2 B).  These results were observed in multiple mice at 
multiple time points, illustrating the persistence of this result. 
Isolation of mouse embryonic fibroblasts  
In order to develop a tissue culture model in which the role of FADD can be mechanistically 
determined, mouse embryonic fibroblasts (MEFs) were isolated from developing embryos after 9 days 
of gestation.  This in vitro approach allowed for preliminary determination of the role of FADD in cell 
growth (Figure 3 A).  MEFs with the desired phenotypes were successfully isolated and grown up in cell 
culture.  Western blots were used to assess expression patterns which allowed us to separate cell lines 
into distinct experimental cohorts (Figure 3, B).    
A frequent problem associated with Cre recombination is that it is nearly impossible to transfect 
and attain successful recombination in 100% of cells [7].  Having non-recombined cells in culture 
alongside the recombined cells will skew results in the Western blots and cell growth assays to follow.  
In an attempt to gain higher percentage of recombination, we exposed cells to multiple treatments with 
Ad-Cre at a high multiplicity of infection.  While this approach improved overall recombination 
percentages, it was unsuccessful at excising all of the transgene (Figure 3C). In order to definitively 
segregate our transformed cells, we focused on using the GFP tag that was being expressed in any non-
recombined cells.  Frequency associated cell sorting (FACS) allowed for selection of cells that fluoresce 
at a certain wavelength.  In this case, we want to isolate cells that do not fluoresce since these cells must 
have had their FADD:GFP transgene excised by Cre recombinase (Figure 3 C).   Figure 3 D clearly 
demonstrates the principles of FACS and the purpose it served in our experiment.  The GFP+ control is a 
non-Cre treated sample of lung fibroblasts.  Patterning of the quantification data clearly demonstrates a 
shift of cells from GFP+ to GFP- after treatment with Ad-Cre.   
 



















Figure 3: Isolation of mouse embryonic fibroblasts A. Schematic depicting 
isolation of MEFs from experimental cohort and subsequent treatment with 
adenovirus encoding Cre recombinase.  B. Western blot demonstrating 
genotypes of MEFs from cohorts I and II.  FADD + and - control MEF lines 
attained through collaboration with Astar Winoto, UC Berkeley.  C. Western 
blot demonstrating effectiveness of Cre at removing transgene.  Cells were 
exposed to 0, 1, or 2 rounds of infection as labeled. D. Following Ad-Cre 
infection, Cre recombined cells were isolated via FACS.  Positive control 
represents cells sorted before Ad-Cre infection that are actively expressing 
GFP.  Arrows demonstrate shift of GFP negative cells that have been 
recombined by Cre recombinase.  The box drawn closer to the y-axis 
represents cells that do not fluoresce. E. Western blot showing change in p-
ERK expression after treatment of MEFs with epidermal growth factor 
(inducing EGFR based activation of Kras).  F. Pathway demonstrating 
correlation between Kras activation and ERK phosphorylation. 
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In order to demonstrate this correlation experimentally, MEFs were treated with serum 
supplemented with epidermal growth factor (EGF).   EGF is known to bind to the membrane receptor 
EGF-R, which then activates Kras [2].  Western blots demonstrate that upon treatment with EGF, p-ERK 
concentrations increase dramatically, confirming that p-ERK concentration is dependent upon Kras 
activation.  This indicates that p-ERK is a viable surrogate protein to represent the activation state of 
Kras (Figure 2 F). 
FADD increases lung fibroblast proliferation  
 In order to develop an in vitro system that is faithful to lung cancer development, we isolated 
lung fibroblasts from the four murine lines described in Figure 4.  Lung fibroblasts were successfully 
grown up in culture and treated with Ad-Cre in order to activate KrasG12D and excise the FADD:GFP 
transgene.  As expected, cells expressing wild type Kras in both alleles (cell lines III and IV) died after 
approximately 5 passages in culture, while cells expressing KrasG12D on one allele have been 
immortalized.  The difference in growth rate between these strains was apparent when visualizing the 
number of cells in culture (Figure 4 E).  Since not all cells on the plate were infected by the adenovirus, it 
was again necessary to screen for successful transformants using FACS.  
 First, we tried infecting the cells with successive rounds of treatment with Ad-Cre.  While these 
additional treatments reduced the amount of transgene expressing cells in our culture, they were 
unable to infect all cells on the plate.  This result was evidenced by the persistence of transgene 
detected by Western blot (similar to Figure 3 C).  In order to establish an entirely transgene negative cell 
population, we employed frequency associated cell sorting (FACS) after infection with Ad-Cre.  Since 
cells that had been infected successfully would no longer be expressing the FADD:GFP fusion protein, we 
selected for cells that did not fluoresce with GFP.  Protein from this GFP negative cell population was 
analyzed via Western blot, and loss of transgene was confirmed (Figure 4 C). 
 In order to characterize the cancerous potential of our newly attained FADD deficient cell line, 
we assayed for growth rate using the crystal violet growth assay.  In this assay, the ability of plated cells 
to retain crystal violet stain is used as a metric for cell population.  This method was chosen because 
standard cell counting protocols were more tedious and produced less precise results.  The FADD 
deficient cell line grew more slowly and reached a lower maximum population than the FADD 
heterozygous cell line (Figure 4 D).  The phases of cell growth, from exponential to stationary to death, 
are clearly observed in both strains.  However, the cell line expressing FADD undergoes faster 
















Figure 4: Establishment of murine lung fibroblast cell lines. 
A. Isolation of lung fibroblasts and treatment with 
adenovirus encoding Cre recombinase.  Check marks 
indicate actively expressed genes. B. Western blot 
demonstrating expression patterns in cultured lung 
fibroblasts.  C.  Western blot demonstrating effectiveness 
of FACS in separating successful transformants from non-
successful transformants.  D. Crystal violet retention as a 
surrogate for cell growth rate.  Shown are cell growth 
differences secondary to either loss of FADD or activation 
of mutant Kras. E.  Images of lung fibroblasts taken from 
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Materials and Methods 
1.) Mouse Model 
 FADD knockout mice with the conditional FADD:GFP transgene were attained in collaboration 
with researchers at the Kimmel Cancer Center [19].  Inducible KrasG12D mice were attained in 
collaboration with Dr. Tyler Jacks [18]. Establishment of the Kras driven FADD knockout model with 
the FADD:GFP transgene was completed with in house breeding and genotyping.  Mutant Kras 
activation and FADD:GFP excision was achieved in a single step by addition of adenovirus Cre into 
the lungs.  Administration of Ad-Cre was achieved by intranasal injection, during which the mice 
inhale the virus particles.  The inhaled solution was composed of 1 mL of Modified Eagle Medium 
(MEM: Life Sciences), 1.2x1011 plaque forming units of Adenovirus encoding Cre recombinase, and 5 
uL of 2M CaCl2 which precipitated the virus. Mice were anesthetized with isoflurane and held in the 
supine position with the head above the feet.  The Ad-Cre solution was added drop wise to the 
nostril.  All experiments involving animals were carried out in accordance with protocols approved 
by the University Committee on the Use and Care of Animals at the University of Michigan (UCUCA). 
Assessing the expression patterns of lung tissue by the Western blot allowed confirmation of 
dual recombination.  Transgene expression was assessed using α-GFP (Biovision 3999-100) and Kras 
activation was assessed with α-p-ERK (Biovision), a protein downstream of KrasG12D that increases in 
concentration when mutant Kras is activated.    Protein was released from tissues by Dounce 
homogenization in RIPA lysis buffer supplemented with protease inhibitors (Complete Protease 
Inhibitor Cocktail, Roche) and phosphatase inhibitors (PhosSTOP, Roche).  For tissue culture 
samples, cells were scraped from the plate in PBS and incubated for 30 minutes in RIPA lysis buffer.  
Insoluble portions were pelleted, while all soluble protein was quantified via the Lowry assay 
(Biorad).  Equal quantities of protein were resolved on 12% Bis-Tris gels (Invitrogen) and transferred 
onto 0.20 μm nitrocellulose membranes (Invitrogen).  Membranes were blocked for 1 hour in tris-
buffered saline with Tween 20 (TBST) containing 5% milk then incubated with primary overnight at 
4°C before incubation for 1 hour with the appropriate horseradish peroxidase conjugated secondary 
antibody.  All washes were carried out for 30 minutes in fresh TBST.  ECL substrate enabled 
detection of peroxidase activity by chemiluminescence.  Primary antibodies used were α-FADD 
(Epitomics), α-GFP (Biovision), α-p-ERK (Biovision), or HRP conjugated-β-Actin (Biovision). 
 
2.) Histology 
Mice were sacrificed by CO2 asphyxiation followed by cervical dislocation.  Thoracic cavity was 
exposed by incisions along upper midline and transverse lines followed by removal of ventral rib 
cage.   Lungs were perfused with 10 mL phosphate buffered saline (PBS) solution by injection into 
the right ventricle.  Following perfusion, heart and lungs were removed and samples of lung were 
snap-frozen for subsequent protein and DNA analysis.  Remaining lung tissue was either fixed in 
formalin for histology or processed for lung fibroblast isolation.   
After 48 hours in formalin, histology samples were placed in 70% ethanol and sent to the Tissue 
Core at the University of Michigan Comprehensive Cancer Center to be cut and affixed to slides 
using standard techniques.  Washes with xylenes then ethanol removed paraffin wax and re-
hydrated the tissue to allow for staining.  Antigenic sites were retrieved from formalin induced 
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cross-links by boiling in citrate buffer (Biogenex).  2% H2O2 was used to block any endogenously 
existing peroxidase enzymes.  After blocking in 5% BSA, primary antibody was added by the 
hydrophobic barrier method for an overnight incubation (α-FADD, α-p-ERK).  Biotinylated secondary 
antibody was added for 45 minutes at room temperature, followed by treatment with peroxidase 
conjugated avidin which targeted the biotin on the secondary antibody with high affinity (ABC, 
Vector).  Incubation with peroxidase substrate (DAB, Vector) yielded a brown precipitate demarking 
the protein of interest.  Gross morphology of tissue sections was observed by staining with Gill’s 
haematoxylin (Sigma-Aldrich) and 25% Eosin Y solution.  Slides were immersed in haematoxylin for 3 
minutes before washing with warm tap water, distilled water, 95% ethanol, then immersion in 25% 
Eosin Y for 30 seconds.  Tissues were then dehydrated by washes in ethanol then xylenes.  
Coverglass was affixed with Cytoseal 60 (Thermo Scientific).  
 
3.) Isolation of Cell Lines  
Murine lung fibroblast cells were isolated by mechanical dispersion of perfused lung tissue with 
a sterile scalpel followed by a 30 minute shaking incubation with filtered collagenase media (14mL 
DMEM, 1mg DNase (Roche), 200mcg Collagenase A (Roche)).  Further mechanical digestion was 
achieved by repeated aspiration through an 18 gauge needle.  Cells were then pelleted and 
transferred to MEF media in 10 cm plates to be incubated at 37°C for up to 10 passages.  Adenovirus 
harboring the gene for Cre recombinase (Ad-Cre) was attained from the Vector Core at the 
University of Michigan and was added directly to tissue cultures at a high multiplicity of infection.  
FACS sorting was performed by the Flow Cytometry Core at the University of Michigan Biomedical 
Sciences Research Building. 
To isolate MEFs, pregnant females were sacrificed after 9 days of gestation by CO2 asphyxiation 
and the abdominal cavity was exposed using sterile surgical scissors.  Both uterine horns containing 
the fetuses were removed and placed in PBS on ice.  Each embryo was removed from its amniotic 
sack and the head and red tissue containing liver precursor cells was excised, leaving only fibroblast 
cells which were mechanically dispersed using curved iris scissors.  4 mL of trypsin was added for a 
20 minute incubation at 37°C followed by transfer to a new dish containing specialized MEF media 
(93% Dulbecco’s modified Eagle medium, 5% Fetal Bovine Serum, 1% Non-Essential Amino Acids, 
and 1% Penicillin/Streptomycin/Glutamine solution (Life Sciences)). 
 
4.) Cell Growth Assay  
Cells were grown in triplicate on 12-well tissue culture treated plates.  17,000 cells were 
suspended in 2 mL of specialized MEF media.  Every 24 hours following, a plate was assayed for cell 
population as follows. Cells were fixed to the plate with 4% paraformaldehyde for 15 minutes, then 
stained for 20 minutes with crystal violet solution (0.1% crystal violet, 10% ethanol).  Unabsorbed 
stain was removed by 3 rinses with distilled water.  Absorbed stain was eluted with 2mL of 10% 
acetic acid solution and absorbance of the resultant crystal violet/acetic acid solution was measured 
at 590 nm with a single beam spectrophotometer. 
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Discussion 
 It is known that FADD plays distinct roles in both apoptosis and cell cycle regulation [2, 11].  In 
apoptosis, FADD propagates death inducing signals from membrane receptors to downstream effectors 
such as caspase 3, NF-κB, PARP, and CAD [2].  In the cell cycle, phosphorylation of FADD at serine 194 is 
an essential step for the spindle fiber formation necessary for completion of mitosis [1].  Recent studies 
have associated elevated levels of p-FADD with poor clinical outcome in lung cancer patients [4].   After 
associating FADD with lung cancer, it became necessary to evaluate its exact role in these cancers.  Since 
FADD acts in both an apoptotic and proliferative capacity in the cell, it is equally possible that FADD is 
causing the tumors as it is trying to ameliorate them.  We approached this dilemma by establishing a 
lung cancer model in which FADD expression is a variable.  With this model, we demonstrated that FADD 
acts as an oncogene by promoting unregulated cell growth through the cell cycle.  
 Establishing a lung cancer model faithful to the human disease has been a priority of this 
research thus far.  The murine model is a result of careful breeding protocols using mice from 
collaborators Dr. Tyler Jacks and Dr. Yuhang Zhang [18, 19].  The combination of these models provides 
an elegant system which offers us the opportunity to mechanistically investigate the role of FADD in 
lung cancer.  The combination of a KrasG12D driven lung cancer with conditional FADD expression through 
a transgene is a novel approach.  This innovative mouse strain was further used to establish cell culture 
model systems of embryonic fibroblasts (MEFs) and lung fibroblasts with different genotypes.  These cell 
lines provide the basis for most experimentation offered thus far.   
 Using lung fibroblasts, we were able to demonstrate that FADD deficient cell lines grew more 
slowly than equivalent cells with FADD.  Since FADD helped cells to grow more aggressively in culture, it 
can be concluded that FADD is acting in an oncogenic capacity.  Mechanistically, this conclusion suggests 
that FADD acts in cancer cells in one of two likely ways.  First, it is possible that FADD abandons its role 
as an apoptosis signaling protein.  This would result in the loss of essential apoptosis signals that are 
sent to tumorigenic cells by the immune system.  If FADD enabled the cell to ignore these signals, it is 
conceivable that this cell would then be capable to developing into a tumor.  Second, FADD’s role as an 
oncogene may be a result of its malfunction in the cell cycle.  If FADD promotes cell cycle progression 
beyond the confines of deliberate cell growth and proliferation, then it may lead to tumor development.  
Regardless of the mechanism, these results confirm our hypothesis that FADD acts as an oncogene by 
enabling proliferation of lung fibroblasts in lung adenocarcinomas. 
Thus far, analysis of lung cross-sections by histology have been successful at implicating KrasG12D 
activation in tumor development, but the impact of FADD is less clear.  Preliminary data confirms 
expectations that FADD increases the number and severity of tumors and lesions, but this data is not yet 
statistically significant.  Immunohistochemistry performed on these cross-sections has been useful in 
linking p-ERK expression to mutant Kras expression.  The unexpected finding that p-ERK is found to be in 
lower concentrations in FADD null tissues is likely to be a result of cell cycle regulation.  Since FADD plays 
an important role in progressing through the cell cycle, cells without FADD are not able to proceed 
through the cell cycle as efficiently.  P-ERK is known to play a role in promoting cell cycle progression, so 
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it is therefore up-regulated in dividing cells.  Since FADD null cells do not divide as often, p-ERK is not 
expressed in as high of concentrations. 
 In order to more extensively characterize the role of FADD in lung cancer, this mouse model is 
currently being used to evaluate tumor growth in vivo as it relates to FADD expression.   A significant 
amount of work has already been invested in histological analysis of lungs from each experimental 
group at several time points.  We hope to use histology to scale the severity of the lung cancer.  This 
ranking can then be cross-referenced with the genotype of the sample in hopes of demonstrating the 
effects of FADD on lung cancers in vivo.  Essentially, these results are expected to mirror those observed 
in the lung fibroblast culture, in which FADD presence acted as an oncogene by exacerbating tumors.  
We have experimented with several mechanisms for scaling tumor burden.  Computational algorithms 
have been used to calculate functional lung volume from a cross section of the lung.  Having a lower 
functional lung volume is indicative of more advanced tumors that have penetrated farther into the 
healthy viscera of the lungs.  Another approach that has proven very successful in scaling tumor burden 
is computer tomography (CT) scanning of 3-dimensional lung space.  Preliminary results from other 
investigators in the Rehemtulla laboratory have drawn a strong correlation between FADD and more 
severe lung cancers using this method (Data not shown).  Another approach that is in progress is 
staining of histology samples with Masson’s Trichome.  This stain is capable of identifying collagen 
bundles in the lung that are characteristic of tumorous lesions.  Lungs with more collagen can therefore 
be assumed to have a greater tumor burden.  Finally, immunohistochemical analysis targeting Ki-67 will 
provide a diagnostic for cell cycle activity.  Ki-67 is a protein that is present only during active phases of 
the cell cycle.  Since accelerated cell growth and division is a hallmark of cancer, Ki-67 will serve as a 
tumor indicator.  Determining the distribution of Ki-67 in a lung cross-section will allow us to determine 
where the tumors are growing and how severe they may be. 
The second reason for focusing on histology is the potential for associating increased FADD 
concentration with the localization of the tumors themselves.  Thus far, all protein has been taken from 
whole lung homogenates.   This means that the origin of the increased FADD may be from tumor tissue 
or healthy tissue.  It would strengthen the existing results if we could confirm that FADD up-regulation is 
a tumor specific phenomenon.  Thus far, none of the FADD antibodies have been effective at targeting 
FADD in our immunohistochemistry protocol. 
 Future directions of this research will involve a more in-depth evaluation of the post-
transcriptional modification of FADD.  Orthotopic tumor models are designed to illuminate the 
characteristics of cells grown in vitro by introducing them to an in vivo environment.  This experiment 
involves injecting cells from tissue culture back into athymic mice.  Previous research has correlated p-
FADD, not total FADD, with poor clinical prognosis in lung cancer [4, 20].  In order to study how the 
phosphorylation state of FADD impacts the cellular environment, experiments are being designed using 
mice that express a non-phosphorylatable form of FADD.  This mutant FADD, with a mutation at the 
phosphorylation site at serine 191 will enable the evaluation of mice that are unable to phosphorylate 
FADD.  Additionally, mutating the phosphorylation site at serine 191 to become constitutively 
phosphorylated will allow for amplification of p-FADD’s effects on the cell.   Both mutant forms of FADD 
will be transfected into cultured lung fibroblasts without endogenous FADD expression.  These cells will 
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then be injected into mice via the tail vein, where they will target the lungs and develop into tumors 
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